Drug Detail

Information about Tafinlar + Mekinist

Generic Name	Dabrafenib +
IND
Brand Name (US)	Tafinlar + Mekinist
Manufacturer	GlaxoSmithKline
Drug Type	Kinase inhibitor
Delivery	Oral
Approval Status	Approved for a non-GIST cancer
Indications	Melanoma with BRAF mutations
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block BRAF
Drug Category	BRAF Inhibitor + MEK Inhibitor

For GIST with BRAF mutation.

Links
Trials of this drug
	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Trial results